Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alector, Inc. stock logo
ALEC
Alector
$3.13
+6.1%
$2.13
$0.87
$6.37
$316.79M0.99885,639 shs707,331 shs
AlloVir, Inc. stock logo
ALVR
AlloVir
$4.44
-11.4%
$3.07
$7.96
$24.15
$22.39M0.6315,685 shs353,215 shs
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$3.32
-1.8%
$2.47
$1.09
$7.14
$236.28M2.981.43 million shs1.27 million shs
Replimune Group, Inc. stock logo
REPL
Replimune Group
$3.46
-39.4%
$6.43
$2.68
$17.00
$270.09M0.514.02 million shs27.60 million shs
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$9.36
+3.7%
$8.77
$5.03
$13.15
$472.81M1.17916,757 shs349,929 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alector, Inc. stock logo
ALEC
Alector
+6.88%+3.87%+38.50%+102.05%-47.70%
AlloVir, Inc. stock logo
ALVR
AlloVir
+35.04%+7.05%+103.66%+94.94%-70.96%
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-0.88%+28.03%+18.18%+134.72%-47.68%
Replimune Group, Inc. stock logo
REPL
Replimune Group
-1.38%-4.67%+7.13%-39.83%-48.23%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
-2.48%-5.64%+3.67%+5.37%-30.27%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alector, Inc. stock logo
ALEC
Alector
$3.13
+6.1%
$2.13
$0.87
$6.37
$316.79M0.99885,639 shs707,331 shs
AlloVir, Inc. stock logo
ALVR
AlloVir
$4.44
-11.4%
$3.07
$7.96
$24.15
$22.39M0.6315,685 shs353,215 shs
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$3.32
-1.8%
$2.47
$1.09
$7.14
$236.28M2.981.43 million shs1.27 million shs
Replimune Group, Inc. stock logo
REPL
Replimune Group
$3.46
-39.4%
$6.43
$2.68
$17.00
$270.09M0.514.02 million shs27.60 million shs
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$9.36
+3.7%
$8.77
$5.03
$13.15
$472.81M1.17916,757 shs349,929 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alector, Inc. stock logo
ALEC
Alector
+6.88%+3.87%+38.50%+102.05%-47.70%
AlloVir, Inc. stock logo
ALVR
AlloVir
+35.04%+7.05%+103.66%+94.94%-70.96%
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-0.88%+28.03%+18.18%+134.72%-47.68%
Replimune Group, Inc. stock logo
REPL
Replimune Group
-1.38%-4.67%+7.13%-39.83%-48.23%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
-2.48%-5.64%+3.67%+5.37%-30.27%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alector, Inc. stock logo
ALEC
Alector
2.29
Hold$4.1733.12% Upside
AlloVir, Inc. stock logo
ALVR
AlloVir
0.00
N/AN/AN/A
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
2.67
Moderate Buy$8.50156.02% Upside
Replimune Group, Inc. stock logo
REPL
Replimune Group
2.10
Hold$6.5087.86% Upside
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
2.83
Moderate Buy$28.38203.15% Upside

Current Analyst Ratings Breakdown

Latest REPL, ALVR, RGNX, ALEC, and CCCC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/17/2025
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$8.00
9/16/2025
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$8.00
9/15/2025
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
Stephens
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeEqual WeightOverweight$3.00 ➝ $6.00
9/8/2025
Replimune Group, Inc. stock logo
REPL
Replimune Group
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/8/2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$52.00
9/8/2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$34.00
9/3/2025
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$8.00
9/3/2025
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$8.00
8/22/2025
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
8/19/2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$34.00
8/8/2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$21.00 ➝ $17.00
(Data available from 9/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alector, Inc. stock logo
ALEC
Alector
$100.56M3.15N/AN/A$1.29 per share2.43
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/A$29.35 per shareN/A
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$35.58M6.64N/AN/A$3.06 per share1.08
Replimune Group, Inc. stock logo
REPL
Replimune Group
N/AN/AN/AN/A$5.40 per shareN/A
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$155.78M3.04N/AN/A$5.24 per share1.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alector, Inc. stock logo
ALEC
Alector
-$119.05M-$1.16N/AN/AN/A-142.10%-112.06%-26.37%11/5/2025 (Estimated)
AlloVir, Inc. stock logo
ALVR
AlloVir
-$190.42M-$20.23N/AN/AN/A-71.03%-61.27%11/10/2025 (Estimated)
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$105.32M-$1.58N/AN/AN/A-325.88%-53.91%-33.26%10/30/2025 (Estimated)
Replimune Group, Inc. stock logo
REPL
Replimune Group
-$247.30M-$3.24N/AN/AN/AN/A-69.34%-52.81%11/11/2025 (Estimated)
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
-$227.10M-$3.44N/AN/AN/A-112.70%-66.95%-34.14%11/5/2025 (Estimated)

Latest REPL, ALVR, RGNX, ALEC, and CCCC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Alector, Inc. stock logo
ALEC
Alector
-$0.45-$0.30+$0.15-$0.30$2.76 million$7.87 million
8/7/2025Q2 2025
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$0.38-$0.37+$0.01-$0.37$5.24 million$6.46 million
8/7/2025Q1 2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
-$0.83-$0.95-$0.12-$0.95$0.50 millionN/A
8/7/2025Q2 2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
-$1.13-$1.38-$0.25-$1.38$40.87 million$21.36 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alector, Inc. stock logo
ALEC
Alector
N/AN/AN/AN/AN/A
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/AN/A
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/AN/AN/AN/AN/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
N/AN/AN/AN/AN/A
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alector, Inc. stock logo
ALEC
Alector
0.13
3.78
3.78
AlloVir, Inc. stock logo
ALVR
AlloVir
N/A
86.78
86.78
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/A
5.06
5.06
Replimune Group, Inc. stock logo
REPL
Replimune Group
0.21
6.94
6.94
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
N/A
3.13
3.13

Institutional Ownership

CompanyInstitutional Ownership
Alector, Inc. stock logo
ALEC
Alector
85.83%
AlloVir, Inc. stock logo
ALVR
AlloVir
66.05%
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
78.81%
Replimune Group, Inc. stock logo
REPL
Replimune Group
92.53%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
88.08%

Insider Ownership

CompanyInsider Ownership
Alector, Inc. stock logo
ALEC
Alector
9.70%
AlloVir, Inc. stock logo
ALVR
AlloVir
32.07%
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
8.73%
Replimune Group, Inc. stock logo
REPL
Replimune Group
5.20%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
12.79%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alector, Inc. stock logo
ALEC
Alector
270101.21 million91.39 millionOptionable
AlloVir, Inc. stock logo
ALVR
AlloVir
1105.04 million3.43 millionOptionable
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
15071.17 million64.96 millionOptionable
Replimune Group, Inc. stock logo
REPL
Replimune Group
21078.06 million74.00 millionOptionable
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
37050.51 million44.05 millionOptionable

Recent News About These Companies

Q3 Earnings Forecast for REGENXBIO Issued By Leerink Partnrs
REGENXBIO's (RGNX) Buy Rating Reaffirmed at HC Wainwright
REGENXBIO (NASDAQ:RGNX) Earns Buy Rating from HC Wainwright
Chardan Capital Reaffirms Buy Rating for REGENXBIO (NASDAQ:RGNX)
REGENXBIO Inc. $RGNX Shares Acquired by PDT Partners LLC

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alector stock logo

Alector NASDAQ:ALEC

$3.13 +0.18 (+6.10%)
Closing price 04:00 PM Eastern
Extended Trading
$3.12 0.00 (-0.16%)
As of 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

AlloVir stock logo

AlloVir NASDAQ:ALVR

$4.44 -0.57 (-11.38%)
As of 09/17/2025

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

C4 Therapeutics stock logo

C4 Therapeutics NASDAQ:CCCC

$3.32 -0.06 (-1.78%)
Closing price 04:00 PM Eastern
Extended Trading
$3.33 +0.01 (+0.30%)
As of 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Replimune Group stock logo

Replimune Group NASDAQ:REPL

$3.46 -2.25 (-39.40%)
Closing price 04:00 PM Eastern
Extended Trading
$3.48 +0.02 (+0.43%)
As of 07:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

REGENXBIO stock logo

REGENXBIO NASDAQ:RGNX

$9.36 +0.33 (+3.65%)
Closing price 04:00 PM Eastern
Extended Trading
$9.23 -0.13 (-1.39%)
As of 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.